BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30626634)

  • 1. Cell-Free
    Jung M; Ellinger J; Gevensleben H; Syring I; Lüders C; de Vos L; Pützer S; Bootz F; Landsberg J; Kristiansen G; Dietrich D
    Clin Chem; 2019 Apr; 65(4):559-568. PubMed ID: 30626634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients.
    de Vos L; Gevensleben H; Schröck A; Franzen A; Kristiansen G; Bootz F; Dietrich D
    Clin Epigenetics; 2017; 9():125. PubMed ID: 29213339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.
    Bergheim J; Semaan A; Gevensleben H; Groening S; Knoblich A; Dietrich J; Weber J; Kalff JC; Bootz F; Kristiansen G; Dietrich D
    Br J Cancer; 2018 May; 118(9):1217-1228. PubMed ID: 29610456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study.
    Schröck A; Leisse A; de Vos L; Gevensleben H; Dröge F; Franzen A; Wachendörfer M; Schröck F; Ellinger J; Teschke M; Wilhelm-Buchstab T; Landsberg J; Holdenrieder S; Hartmann G; Field JK; Bootz F; Kristiansen G; Dietrich D
    Clin Chem; 2017 Jul; 63(7):1288-1296. PubMed ID: 28515105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood: An Observational Prospective Study.
    de Vos L; Jung M; Koerber RM; Bawden EG; Holderried TAW; Dietrich J; Bootz F; Brossart P; Kristiansen G; Dietrich D
    J Mol Diagn; 2020 Jul; 22(7):920-933. PubMed ID: 32361006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Cell-Free SHOX2 DNA Methylation Is a Predictive, Prognostic, and Monitoring Biomarker in Adjuvant and Palliative Anti-PD-1-Treated Melanoma.
    Fietz S; Diekmann E; de Vos L; Zarbl R; Hunecke A; Glosch AK; Färber M; Sirokay J; Hoffmann F; Fröhlich A; Franzen A; Strieth S; Landsberg J; Dietrich D
    Clin Chem; 2024 Mar; 70(3):516-527. PubMed ID: 38300881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter hypermethylation of
    Branchi V; Schaefer P; Semaan A; Kania A; Lingohr P; Kalff JC; Schäfer N; Kristiansen G; Dietrich D; Matthaei H
    Clin Epigenetics; 2016; 8():133. PubMed ID: 27999621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients.
    Dietrich D; Hasinger O; Liebenberg V; Field JK; Kristiansen G; Soltermann A
    Diagn Mol Pathol; 2012 Jun; 21(2):93-104. PubMed ID: 22555092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.
    Weiss G; Schlegel A; Kottwitz D; König T; Tetzner R
    J Thorac Oncol; 2017 Jan; 12(1):77-84. PubMed ID: 27544059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma.
    Kneip C; Schmidt B; Seegebarth A; Weickmann S; Fleischhacker M; Liebenberg V; Field JK; Dietrich D
    J Thorac Oncol; 2011 Oct; 6(10):1632-8. PubMed ID: 21694641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
    Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients.
    Dietrich D; Weider S; de Vos L; Vogt TJ; Färber M; Zarbl R; Hunecke A; Glosch AK; Gabrielpillai J; Bootz F; Bauernfeind FG; Kramer FJ; Kristiansen G; Brossart P; Strieth S; Franzen A
    Clin Chem; 2023 Sep; 69(9):1050-1061. PubMed ID: 37477541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Dynamics of Quantitative
    Krausewitz P; Kluemper N; Richter AP; Büttner T; Kristiansen G; Ritter M; Ellinger J
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer.
    Huang W; Huang H; Zhang S; Wang X; Ouyang J; Lin Z; Chen P
    Cancer Control; 2020; 27(1):1073274820969703. PubMed ID: 33167712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites.
    Jung M; Pützer S; Gevensleben H; Meller S; Kristiansen G; Dietrich D
    Clin Epigenetics; 2016; 8():24. PubMed ID: 26937257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
    Mendoza-Pérez J; Gu J; Herrera LA; Tannir NM; Zhang S; Matin S; Karam JA; Wood CG; Wu X
    Cancer; 2017 Sep; 123(18):3617-3627. PubMed ID: 28543182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of DNA methylation levels of
    Grossi I; Assoni C; Lorini L; Smussi D; Gurizzan C; Grisanti S; Paderno A; Mattavelli D; Piazza C; Pelisenco IA; De Petro G; Salvi A; Bossi P
    Oncol Rep; 2024 Mar; 51(3):. PubMed ID: 38299234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
    Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
    Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation of neural EGFL like 1 (NELL1) is associated with advanced disease and the metastatic state of renal cell cancer patients.
    Peters I; Dubrowinskaja N; Hennenlotter J; Antonopoulos WI; Von Klot CAJ; Tezval H; Stenzl A; Kuczyk MA; Serth J
    Oncol Rep; 2018 Dec; 40(6):3861-3868. PubMed ID: 30272321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.